Full-Time
Manufacturing Operator 2
Cooper Companies
201-500 employees
Global medical devices and vision care
No salary listed
Cornwall, UK
In Person
 Manufacturing & Production Operations (1) |
|---|
Get referred to Cooper Companies
See people who can refer or advise you
- Typically, 6–18 months manufacturing experience, or equivalent demonstrated competence.
- Secondary school education or equivalent
- Competent use of work instructions, drawings, and routings
- Basic problem-solving skills
- Good attention to detail and quality awareness
- The Operator Level 2 is responsible for the accurate and timely completion of production activities and comfortably support and train out an entire product line within the Capital Fertility Equipment Portfolio at Falmouth.
- This will be done in accordance with Production Orders, routings, and approved Work Instructions.
- The role requires consistent application of quality standards, effective time management, and the ability to identify and escalate process or quality issues.
Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.
Company Size
201-500
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
1958
Get referred to Cooper Companies
See people who can refer or advise you
Simplify's Take
What believers are saying
- Management kept CooperSurgical and expanded buybacks to $3 billion on September 9, 2026.
- MiSight grew 20% and MyDay posted double-digit growth in fiscal Q3 2026.
- Free cash flow hit $273 million quarterly, supporting deleveraging and repurchases.
What critics are saying
- U.S. channel destocking cut CooperVision Q3 revenue to $717 million and hits Q4.
- CooperSurgical faces Miudella competition after Organon's February 2026 licensing deal.
- Accrued litigation liability reached $316.5 million in July 2026, threatening cash and multiples.
What makes Cooper Companies unique
- CooperVision leads premium daily lenses; MyDay, MiSight, and torics drove 2026 growth.
- CooperSurgical owns ParaGard, the only U.S. non-hormonal copper IUD franchise.
- Global scale across 130 countries and 15,000 employees supports resilient distribution and R&D.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Health Insurance
401(k) Retirement Plan
Life Insurance
Wellness Program
Professional Development Budget
Company News
The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.
The Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.11 by 3.6%. However, revenues of $1.066 billion missed estimates of $1.099 billion by 3.0%, impacted by US channel inventory reductions in its CooperVision segment. Shares fell 15.9% in after-hours trading following the announcement. The stock has declined 22.5% year-to-date, contrasting with the S&P 500's 11% gain. CooperVision revenues remained flat year over year at $717 million, pressured by inventory destocking. CooperSurgical grew 2% to $349.2 million. MiSight delivered 20% organic growth, whilst MyDay products recorded double-digit growth across multiple categories.
Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.
CooperCompanies reported first-quarter revenues of $1.08 billion, up 7.9% year-on-year and exceeding analyst expectations by 2.7%. The medical device manufacturer, which focuses on vision care contact lenses and women's health products, also beat earnings per share estimates. The result came as the medical devices and supplies sector reported a strong quarter overall. Five tracked companies in the diversified category beat consensus revenue estimates by 2.9% on average, though next quarter's guidance came in 2.2% below expectations. Despite delivering the weakest full-year guidance update in the group, CooperCompanies' shares have risen 9% since reporting. The stock currently trades at $67.62.
CooperCompanies reported second-quarter revenue of $1.07 billion, missing analyst estimates of $1.10 billion. The medical device company's sales were flat year-on-year, whilst its operating margin improved to 20.8% from 16.6% in the same quarter last year. The company lowered its full-year revenue guidance to $4.24 billion at the midpoint, down from $4.30 billion, representing a 1.5% decrease. Adjusted earnings per share guidance was also reduced to $4.53 at the midpoint, a 1.9% decrease. Despite beating analyst expectations with adjusted EPS of $1.15 versus estimates of $1.12, the company's shares fell 16.8% following the announcement. CEO Al White cited reduced US channel inventory at CooperVision as weighing on results. CooperCompanies develops medical devices for vision care and women's health.